TrialHaematologica2017

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.

Nicola Gökbuget et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.